RT journal article
T1 Empagliflozin reduces brain pathology in Alzheimer’s disease and type 2 diabetes
A1 Hierro Bujalance, Carmen
A1 García Alloza, Mónica
A2 BiomedicinaBiotecnología y Salud Pública
AB Alzheimer’s disease (AD) and type 2 diabetes(T2D): More than 55 million people suffer fromdementia, and it is expected that over 150 millionpeople will suffer from this disease by 2050. ADis the most common type of dementia and whileaging remains the main risk factor to suffer it,previous studies have also shown that metabolicdisorders, and T2D specifically, are also majorcontributors (Wang et al., 2012). The prevalenceof diabetes has reached 537 million peopleworldwide and these figures are expected to keeprising (Ahmad et al., 2022). All things considered,both diseases are a great challenge for health.
PB Wolters Kluwer Medknow Publications
SN 1876-7958
YR 2024
FD 2024
LK http://hdl.handle.net/10498/32070
UL http://hdl.handle.net/10498/32070
LA eng
DS Repositorio Institucional de la Universidad de Cádiz
RD 15-nov-2026